Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) reported positive results from a Phase IIb AURA-LV study for lupus nephritis lifting the stock price up 37 cents to close at $3.01.
Aurinia Pharmaceuticals reports positive study results
September 30, 2016 at 18:51 PM EDT
